Key result
Diffuse esophageal spasm was associated with apnea and bradycardia in a newborn infant, and the condition improved after administration of the anticholinergic agent glycopyrrolate.
Why the study?
Does glycopyrrolate improve apnea and bradycardia associated with esophageal spasm in a newborn infant?
Does glycopyrrolate improve apnea and bradycardia associated with esophageal spasm in a newborn infant?
Glycopyrrolate administration improved apnea and bradycardia associated with esophageal spasm in a newborn infant, suggesting a vagally mediated mechanism.
Hypothesis-generating for glycopyrrolate in neonatal esophageal spasm-associated apnea-bradycardia; prospective studies needed before clinical use.
A newborn infant was found to have diffuse esophageal spasm in association with apnea and bradycardia. This association has not been physiologically documented before. The infant's condition improved after the administration of glycopyrrolate, an anticholinergic agent. It is speculated that the association of esophageal spasm and bradycardia may be mediated by the vagus.
No takes yet. Share an insight, caveat, or question.
Fontán et al. (1984) studied this question. Diffuse esophageal spasm was associated with apnea and bradycardia in a newborn infant, and the condition improved after administration of the anticholinergic agent glycopyrrolate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: